Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 8/20 | 1.00 |
| ▸ | TCF4 | P15884 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | CDH1 | P12830 | 2/20 | 1.00 |
| ▸ | APC | P25054 | 2/20 | 1.00 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | SYK | P43405 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | MGAM | O43451 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SI | P14410 | 2/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29525736 | 1.00 | CTNNB1 (1.00) | CTNNB1TCF4MAPTCDH1APC | |
| SCHEMBL29372562 | 1.00 | CTNNB1 (1.00) | CTNNB1TCF4MAPTCDH1APC | |
| SCHEMBL29711243 | 0.90 | CTNNB1 (0.81) | CTNNB1TCF4MAPTCDH1APC | |
| SCHEMBL29711326 | 0.88 | CTNNB1 (0.78) | CTNNB1TCF4MAPTCDH1APC | |
| Calphostin C SCHEMBL13827621 | 0.88 | CTNNB1 (0.79) | CTNNB1TCF4MAPTCDH1APC | |
| Calphostin C SCHEMBL15185703 | 0.88 | CTNNB1 (0.79) | CTNNB1TCF4MAPTCDH1APC | |
| SCHEMBL29711331 | 0.87 | CTNNB1 (0.76) | CTNNB1TCF4MAPTCDH1APC | |
| SCHEMBL16500263 | 0.84 | CTNNB1 (0.73) | CTNNB1TCF4MAPTCDH1APC | |
| SCHEMBL13820267 | 0.80 | CTNNB1 (0.67) | CTNNB1TCF4MAPTCDH1APC | |
| SCHEMBL22965109 | 0.77 | CTNNB1 (0.63) | CTNNB1TCF4MAPTCDH1APC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| US-9730926-B2 | Combination therapy using bispecific anti-c-Met/anti-EGFR antibody and c-Src inhibitor | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-08-15 | — | — | US | claimed |
| US-20150216972-A1 | COMBINATION THERAPY USING BISPECIFIC ANTI-C-MET/ANTI-EGFR ANTIBODY AND C-SRC INHIBITOR | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2015-08-06 | — | — | US | claimed |
| EP-4567102-A1 | METHODS FOR ISOLATING EMBRYONIC STEM CELLS FROM AVIAN EMBRYONIC CELLS | Suprême (FR) | 2025-06-11 | — | — | EP | disclosed |
| US-12036218-B2 | Modulators of airway basal cells for the treatment or prevention of lung diseases | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. (DE) | 2024-07-16 | — | — | US | disclosed |
| US-20230338340-A1 | Methods of Treating Cystic Fibrosis | DARTMOUTH COLLEGE (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338340-A1 | Methods of Treating Cystic Fibrosis | DARTMOUTH COLLEGE (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338340-A1 | Methods of Treating Cystic Fibrosis | DARTMOUTH COLLEGE (US) | 2023-10-26 | — | — | US | disclosed |
| EP-3784240-B1 | WNT6 AS GLIOBLASTOMA ONCOGENIC BIOMARKER, AND USES OF INHIBITORS THEREOF FOR TREATING WNT6-OVEREXPRESSING GLIOBLASTOMA | UNIV DO MINHO (PT) | 2023-09-20 | — | — | EP | disclosed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | disclosed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | disclosed |
| EP-3784240-A2 | A NOVEL ONCOGENE BIOMARKER, METHOD AND USES THEREOF | Universidade do Minho (PT) | 2021-03-03 | — | — | EP | disclosed |
| US-20210041443-A1 | WNT6 AS GLIOBLASTOMA ONCOGENIC BIOMARKER, AND USES OF INHIBITORS THEREOF | UNIVERSIDADE DO MINHO (PT) | 2021-02-11 | — | — | US | disclosed |
| US-10624949-B1 | Methods for treating diseases related to the wnt pathway | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) | 2020-04-21 | — | — | US | disclosed |
| US-9730926-B2 | Combination therapy using bispecific anti-c-Met/anti-EGFR antibody and c-Src inhibitor | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-08-15 | — | — | US | disclosed |
| US-20150216972-A1 | COMBINATION THERAPY USING BISPECIFIC ANTI-C-MET/ANTI-EGFR ANTIBODY AND C-SRC INHIBITOR | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2015-08-06 | — | — | US | disclosed |
| EP-2431386-B1 | Na+/Mg2+ exchanger | FBN LEIBNIZ INST FÜR NUTZTIERBIOLOGIE (DE) | 2015-02-25 | — | — | EP | disclosed |
| WO-2010043561-A2 | REGENERATIVE THERAPY | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2010-04-22 | — | — | WO | disclosed |
| EP-2177218-A1 | Regenerative therapy | Medizinische Universität Wien (AT) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216972-A1 | COMBINATION THERAPY USING BISPECIFIC ANTI-C-MET/ANTI-EGFR ANTIBODY AND C-SRC INHIBITOR | SRC, MET, EGFR | CTNNB1 1049/4885TCF4 3100/4885MAPT 1116/4885 |
| US-20230338340-A1 | Methods of Treating Cystic Fibrosis | CFTR, DAB2IP, CTTN | CTNNB1 312/4885TCF4 1501/4885MAPT 4546/4885 |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | CTNNB1 1218/4885TCF4 1490/4885MAPT 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.